June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Safety and efficacy of fluocinolone acetonide intravitreal implant (Iluvien®) in patients with chronic diabetic macular edema in a real-life setting
Author Affiliations & Notes
  • Monica Santos
    Ophthalmology, Centro Hospitalar de Leiria, Leiria, Portugal
  • António Campos
    Ophthalmology, Centro Hospitalar de Leiria, Leiria, Portugal
  • Arminda Neves
    Ophthalmology, Centro Hospitalar de Leiria, Leiria, Portugal
  • Pedro Alfaiate
    Ophthalmology, Centro Hospitalar de Leiria, Leiria, Portugal
  • Joana Pereira
    Ophthalmology, Centro Hospitalar de Leiria, Leiria, Portugal
  • João Paulo Castro e Sousa
    Ophthalmology, Centro Hospitalar de Leiria, Leiria, Portugal
  • Footnotes
    Commercial Relationships   Monica Santos, None; António Campos, None; Arminda Neves, None; Pedro Alfaiate, None; Joana Pereira, None; João Paulo Castro e Sousa, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 5032. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Monica Santos, António Campos, Arminda Neves, Pedro Alfaiate, Joana Pereira, João Paulo Castro e Sousa; Safety and efficacy of fluocinolone acetonide intravitreal implant (Iluvien®) in patients with chronic diabetic macular edema in a real-life setting. Invest. Ophthalmol. Vis. Sci. 2017;58(8):5032.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The FAME study demonstrated the efficacy and safety of the fluocinolone acetonide (FAc) implant, ILUVIEN®, in eyes of patients with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. The purpose of this study was to evaluate the efficacy and safety of FAc 190 μg implant in the treatment of DME in a real world basis.

Methods : This non-interventional, retrospective, case series evaluated 20 eyes of 16 patients with mean DME duration of 6 years, that did not respond sufficiently to previous treatments (laser, anti-VEGF or corticosteroids) and received one single intravitreal FAc implant (190 μg). Main outcomes were measured at baseline, 1, 3 and 6 months and included: best-corrected visual acuity (BCVA), central macular thickness (CMT), macular volume (MV) and intraocular pressure (IOP).

Results : Twenty eyes of sixteen patients were included, 11 males and 5 females, with a mean age of 67,45±10,73 years. Seventeen eyes were pseudophakic and 3 were phakic. All eyes treated received prior treatments: laser (19 eyes), intravitreal agents including bevacizumab (2 eyes), ranibizumab (16 eyes), aflibercept (3 eyes), triamcinolone (11 eyes) and dexamethasone implant (11 eyes). Seven eyes underwent previous vitrectomy. At baseline mean (±standard deviation) BCVA was 50,25±12,23 ETDRS letters, CMT 516.60±176.96 μm, MV 11.23±2.69 mm3 and IOP 14.47±3.57 mmHg. The mean change of BCVA and IOP from baseline to month 6 did not show a significant difference. At month 3, there was a statistical significant reduction of CMT to 358,85±115,28 μm (p = 0.021) that was maintained at the 6th month, 315,22±89,46 μm (p = 0.008). The mean MV at months 3 and 6 was 9,92±1,15 mm3 (p = 0.071) and 9,30±1,14 mm3 (p = 0.0521) respectively, approaching marginal levels of significance when compared with baseline.

Conclusions : This study demonstrated that intravitreal FAc implant (Iluvien®) is effective and safe in non-naïve eyes with chronic DME. The results showed a significant and sustained decrease in CMT and MV. There was no statistically significant change in IOP. From present data in real-life setting at our site and recent data published from EARLY study, authors may advise the treatment with FAc earlier in non-naïve eyes with chronic DME.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×